Fig. 1.AsS decreases the viability of HCC cells. (A) The
chemical structure of AsS. (B) The cytotoxicity of AsS
was evaluated against HepG2, Hep3B, and L02 for 24 h. (C) HepG2 and Hep3B cells
were treated with AsS for 24, 48, or 72 h at different concentrations
(0, 1, 3, 5, 10, 15, and 20 µM) and the cell viability detected by the
CCK-8 assay. (D) HepG2 and Hep3B cells were treated with DPBS, arsenic sulfide (5
µM), 5-FU (5-fluorouracil, 20 µg/mL), sorafenib (6 µM), and DDP
(cisplatin, 8 µg/mL) for 24 h. (E) The effect of conditioned medium from
AS-treated HCC cells on the proliferation of HUVECs was evaluated by
the CCK-8 assay.